Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI)

Stone GW., 2010, Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease., N Engl J Med., 362, 1663, 10.1056/NEJMoa0910496

Smits PC., 2011, 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. The COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label trial)., J Am Coll Cardiol., 58, 11, 10.1016/j.jacc.2011.02.023

Gomez-Lara J., 2011, Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography., JACC Cardiovasc Interv., 4, 1271, 10.1016/j.jcin.2011.08.016

Diletti R., 2013, Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial., Heart., 99, 98, 10.1136/heartjnl-2012-302598

Diletti R., 2012, ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design., Am Heart J., 164, 654, 10.1016/j.ahj.2012.08.010